efile GRAPHIC print - DO NOT PROCESS | As Filed Data -

**Return of Private Foundation** 

DLN: 93491310012538 OMB No 1545-0052

2017

Form 990-PF

Department of the Treasury

Internal Revenue Service

or Section 4947(a)(1) Trust Treated as Private Foundation ▶ Do not enter social security numbers on this form as it may be made public.
 ▶ Information about Form 990-PF and its instructions is at <a href="www.irs.gov/form990pf">www.irs.gov/form990pf</a>.

Open to Public Inspection

For	caler	ndar year 2017, or tax year beginning 01-01-20	)17 , ar	nd ending 12-31-	2017	
		indation oundation Inc		A Employer ide	entification numbe	r
ın	e Jain F	oundation Inc		20-0284800		
		street (or P O box number if mail is not delivered to street address)  d Avenue NE	Room/suite	<b>B</b> Telephone nu	mber (see instructioi	ns)
			(425) 882-1492			
		, state or province, country, and ZIP or foreign postal code 98115		<b>C</b> If exemption	application is pendin	g, check here
G Ch	neck al	l that apply 🔲 Initial return 🔲 Initial return of a	former public charity	<b>D 1.</b> Foreign org	ganizations, check he	ere . $\square$
		☐ Final return ☐ Amended return			ganızatıons meeting	
		Address change		test, chec	k here and attach co	mputation 🕨 🔲
H Ch	neck tv	pe of organization Section 501(c)(3) exempt private	foundation		indation status was t n 507(b)(1)(A), chec	
_			e private foundation	under section	1 307(D)(1)(A), Cliec	k liele - —
		eet value of all assets at end  J Accounting method	☑ Cash ☐ Accru	al F If the founda	tion is in a 60-month	n termination
of '	year <i>(f</i>	rom Part II, col (c), \$ 28,001,511			n 507(b)(1)(B), chec	
Pa	rt I	Analysis of Revenue and Expenses (The total				(d) Disbursements
		of amounts in columns (b), (c), and (d) may not necessarily	(a) Revenue and expenses per	(b) Net investment income	(c) Adjusted net income	for charitable purposes
		equal the amounts in column (a) (see instructions) )	books	lincome	ilicome	(cash basis only)
	1	Contributions, gifts, grants, etc , received (attach schedule)				
	2	Check ► ✓ If the foundation is <b>not</b> required to attach Sch. B				
	3	Interest on savings and temporary cash investments	4,815	4,815		
	4	Dividends and interest from securities				
	5a	Gross rents				
	ь	Net rental income or (loss)				
ē	6a	Net gain or (loss) from sale of assets not on line 10	4,047,712			
Revenue	ь	Gross sales price for all assets on line 6a 4,047,912				
Re	7	Capital gain net income (from Part IV, line 2)		4,047,712		
	8	Net short-term capital gain				
	9	Income modifications				
	10a	Gross sales less returns and allowances				
	ь	Less Cost of goods sold				
	С	Gross profit or (loss) (attach schedule)				
	11	Other income (attach schedule)	36,139			
	12	Total. Add lines 1 through 11	4,088,666	4,052,527		
	13	Compensation of officers, directors, trustees, etc	361,353			361,353
	14	Other employee salaries and wages	298,532			298,532
6S	15	Pension plans, employee benefits	72,391			72,391
35	16a	Legal fees (attach schedule)	8,528			8,528
X DG	ь	Accounting fees (attach schedule)	<b>9</b> 5,510			5,510
and Administrative Expenses	С	Other professional fees (attach schedule)	55,134			55,134
Ž	17	Interest				
stra	18	Taxes (attach schedule) (see instructions)	80,224			
Ē	19	Depreciation (attach schedule) and depletion				
Ē	20	Occupancy	119,966			119,966
۵ ک	21	Travel, conferences, and meetings	9,976			9,976
ä	22	Printing and publications				
<u>b</u> u	23	Other expenses (attach schedule)	1,209,581			1,209,581
Operating	24	Total operating and administrative expenses.				
<u>pe</u>		Add lines 13 through 23	2,221,195	0		2,140,971
0	25	Contributions, gifts, grants paid	2,226,705			2,226,705
	26	$ \begin{tabular}{ll} \textbf{Total expenses and disbursements.} & \textbf{Add lines 24 and} \\ \textbf{25} & \end{tabular} $	4,447,900	0		4,367,676
	27	Subtract line 26 from line 12	, ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,			
	а	Excess of revenue over expenses and disbursements	-359,234			
	ь	Net investment income (if negative, enter -0-)		4,052,527		
	С	Adjusted net income(If negative, enter -0-)				
	Dana-	work Doduction Act Natice are instructions	1	C-1 N 44333		000 BE (2217)

	-	cash hon interest bearing			
	2	Savings and temporary cash investments	1,720,856	1,146	.980 1,146,980
	3	Accounts receivable			
		Less allowance for doubtful accounts ▶			
	4	Pledges receivable ▶			
		Less allowance for doubtful accounts ▶			
	5	Grants receivable			
	6	Receivables due from officers, directors, trustees, and other			
		disqualified persons (attach schedule) (see instructions)			
	7	Other notes and loans receivable (attach schedule) ▶			
		Less allowance for doubtful accounts ▶			
ķ	8	Inventories for sale or use			
Assets	9	Prepaid expenses and deferred charges	9,549	8	.802 8,802
	10a	Investments—U S and state government obligations (attach schedule)			
	ь	Investments—corporate stock (attach schedule)	20,432,660	20,432	.461 26,639,777
	C C	Investments—corporate bonds (attach schedule)			
	11	Investments—land, buildings, and equipment basis ▶			
		Less accumulated depreciation (attach schedule) ▶	1,410	<b>9</b>	,410 1,410
	12	Investments—mortgage loans			
	13	Investments—other (attach schedule)			
	14	Land, buildings, and equipment basis ▶			
		Less accumulated depreciation (attach schedule) ▶			
	15	Other assets (describe >)		204	.542 204,542
	16	Total assets (to be completed by all filers—see the			
		instructions Also, see page 1, item I)	22,164,475	21,794	.195 28,001,511

18,743

18,744

21,775,451

21,775,451

21,794,195

2

3 4

5

22,134,885

21,775,651

21,775,451

Form **990-PF** (2017)

200

-359,234

29,590

29,590

22,134,885

22,134,885

22,164,475

وچ

12	Investments—mortgage loans	
13	Investments—other (attach schedule)	
14	Land, buildings, and equipment basis ▶	
	Less accumulated depreciation (attach schedule) ▶	
15	Other assets (describe)	<b>%</b> ∑
16	Total assets (to be completed by all filers—see the	
	instructions Also, see page 1, item I) 22,164,475	

Accounts payable and accrued expenses . . . . . .

Foundations that follow SFAS 117, check here ▶

and complete lines 24 through 26 and lines 30 and 31.

Foundations that do not follow SFAS 117, check here ▶

Retained earnings, accumulated income, endowment, or other funds

Total net assets or fund balances (see instructions) . . . . .

Total liabilities and net assets/fund balances (see instructions) .

Total net assets or fund balances at beginning of year—Part II, column (a), line 30 (must agree with end-

Total net assets or fund balances at end of year (line 4 minus line 5)—Part II, column (b), line 30

**Analysis of Changes in Net Assets or Fund Balances** 

Capital stock, trust principal, or current funds . . . . . Paid-in or capital surplus, or land, bldg, and equipment fund

Other liabilities (describe ▶\_

Unrestricted

Temporarily restricted

Permanently restricted .

and complete lines 27 through 31.

of-year figure reported on prior year's return)

Other increases not included in line 2 (itemize)

Enter amount from Part I, line 27a

Add lines 1, 2, and 3 . . . . . .

Decreases not included in line 2 (itemize) ▶

Loans from officers, directors, trustees, and other disqualified persons

Mortgages and other notes payable (attach schedule). . . . . .

Total liabilities(add lines 17 through 22) . . . . . . . . . . . . .

17

18

19 20

21

22

23

24 25

26

27

28 29

30

31 Part III

2

3

4

5

Liabilities

or Fund Balances

Net Assets

List and describe 2-story brick war	(b) How acquired P—Purchase D—Donation	(c) Date acquired (mo , day, yr )	(d) Date sold (mo , day, yr )		
1 a 6000 Berkshire Hathawa	P		2017-05-04		
<b>b</b> 6000 Berkshire Hathawa	•		Р		2017-08-02
c 10800 Berkshire Hathaw	•		Р		2017-10-06
d	ay Incl Del B		'		2017 10 00
-					
e		1	( )		
<b>(e)</b> Gross sales price	(f) Depreciation allowed (or allowable)	Cost or	(g) other basis ense of sale	Gain o	<b>h)</b> or (loss) o minus (g)
<b>a</b> 99	95,803		53	(1)   (1	995,750
	14,606		53		1,044,553
	7,503		94		2,007,409
<u>d</u>	,				
<del></del>					
<u>e</u>					
Complete only for assets	s showing gain in column (h) and ow	<u> </u>			(I) 
(i) FMV as of 12/31/69	( <b>j)</b> Adjusted basis as of 12/31/69	Excess	<b>(k)</b> of col(ı) l(j), ıf any	col (k), but not	h) gain minus less than -0-) <b>or</b> om col (h))
a					995,750
b					1,044,553
c					2,007,409
d					
<u>е</u>					
•	gain or (loss) as defined in sections irt I, line 8, column (c) (see instructions irt I, line 8, column (c) (see instructions is a section in the sections is a section in the section in the section is a section in the section in the section is a section in the section in the section in the section is a section in the section in the section in the section is a section in the section in the section is a section in the section in the section in the section is a section in the section		Part I, line 7	3	4,047,712
Part V Qualification	Under Section 4940(e) for Re	educed Tay on Net	Investment In	come	
(For optional use by domestic p	private foundations subject to the se	ction 4940(a) tax on ne	et investment incom	e )	
	ne section 4942 tax on the distributa		· ·	)   Y	es 🗹 No
· · · · · · · · · · · · · · · · · · ·	ot qualify under section 4940(e) Do nount in each column for each year,				
(a)			I making any entries	(d)	
Base period years Calendar year (or tax year beginning in)	<b>(b)</b> Adjusted qualifying distributions	(c) Net value of noncharitab		Distribution rati (col (b) divided by c	col (c))
2016	4,778,593		25,914,773		0 18440
2015	4,579,194		19,447,830		0 23546
2014	5,582,028		23,001,296		0 24268
2013	3,813,730		23,984,328		0 15901
2012	2,488,458		11,336,068		0 21952
2 Total of line 1, column (	d)		2		1 041065
number of years the four	o for the 5-year base period—divide indation has been in existence if less	than 5 years	<u>3</u>		0 208213
	ncharitable-use assets for 2017 fron	•			26,371,187
<b>5</b> Multiply line 4 by line 3					5,490,824
	ent income (1% of Part I, line 27b)				40,525
					5,531,349
	ions from Part XII, line 4 <b>,</b> eater than line 7, check the box in Pa			g a 1% tax rate Se	4,567,676 e the Part VI
instructions		,	,		<del>-</del>

If yes, did the foundation receive any proceeds or have any net income attributable to the transaction?.

1 List all officers, directors, trustees	, foundation managers a	nd their compensation	(see instructions). (d)	Ι
(a) Name and address	Title, and average hours per week (b) devoted to position	(c) Compensation (If not paid, enter -0-)	Contributions to employee benefit plans and deferred compensation	Expense account (e) other allowances
ee Additional Data Table			2000	
2 Compensation of five highest-paid	T .		Contributions to	ne, enter "NONE."
(a) Name and address of each employee paid more than \$50,000	Title, and average hours per week (b) devoted to position	(c) Compensation	employee benefit plans and deferred (d) compensation	Expense account, (e) other allowances
radley Williams 725 Third Avenue NE Suite 204 eattle, WA 98117	Director Research 40 00	93,25	15,500	
Shira	Dir Patient Relat 40 00	94,94	9 2,571	
725 Third Avenue NE Suite 204 eattle, WA 98117	40 00			
otal number of other employees paid over	¢50,000			
3 Five highest-paid independent con				E".
(a) Name and address of each person	paid more than \$50,000	<b>(b)</b> Type	e of service	(c) Compensation
ONE		_		
		_		
otal number of others receiving over \$50.0	000 for professional services	- -		
Part IX-A Summary of Direct Ch	aritable Activities			
Part IX-A Summary of Direct Ch st the foundation's four largest direct charitable a ganizations and other beneficiaries served, confe	naritable Activities ctivities during the tax year Incrences convened, research pape	lude relevant statistical inform rs produced, etc	nation such as the number of	Expenses
Part IX-A Summary of Direct Ch st the foundation's four largest direct charitable a ganizations and other beneficiaries served, confer 1 While the focus of the Jain Foundation is impact on human health through their right than muscle, and normal aging. The Foundation of every project we fund and keep track conference calls with researchers and signal have the patients diagnosed for who	caritable Activities ctivities during the tax year Inc rences convened, research pape s LGMD2B, the resulting scie elevance to other muscle die undation is hands on in its a of results and agreed upon te visits Our goal continues en we identify treatment(s)	lude relevant statistical inform rs produced, etc entific advances and collab sorders, degenerative dise pproach to funding We cl timelines through quarte to be to fund all possible so they are able to avail t	nation such as the number of coration have a broader eases of tissues other losely monitor progress rly detail oriented approaches to a cure themselves of it Contract	Expenses
Part IX-A Summary of Direct Ch st the foundation's four largest direct charitable a ganizations and other beneficiaries served, confei 1 While the focus of the Jain Foundation is impact on human health through their ru than muscle, and normal aging. The Foundation of every project we fund and keep track conference calls with researchers and signal have the patients diagnosed for who Research Organizations. In 2017 we compart of our therapy development progra provide specialized knowledge and infra	ctivities during the tax year Incrences convened, research pape a LGMD2B, the resulting screelevance to other muscle distinction is hands on in its a of results and agreed upon the visits. Our goal continues are we identify treatment(s) attinued working with Contram CROs are companies tha structure focused on drug d	lude relevant statistical informing produced, etc. entific advances and collabsorders, degenerative disepproach to funding. We clumelines through quarters to be to fund all possible so they are able to avail tot Research Organizations t serve the drug developmiscovery, such as robotic	nation such as the number of coration have a broader eases of tissues other losely monitor progress rly detail oriented approaches to a cure themselves of it Contract s (CROs) as an integral ment industry and	Expenses 775,361
Part IX-A Summary of Direct Chest the foundation's four largest direct charitable a ganizations and other beneficiaries served, confeit while the focus of the Jain Foundation is impact on human health through their rethan muscle, and normal aging. The Foundation of every project we fund and keep track conference calls with researchers and signed have the patients diagnosed for which Research Organizations. In 2017 we compart of our therapy development prograp provide specialized knowledge and infrational part of both the patients and physicians costly. In 2014 we launched a diagnosis specific disease but 34 other similar diseconsortium of family foundations that a reduced the price of diagnosing each patents.	ctivities during the tax year Incrences convened, research pape is LGMD2B, the resulting scielevance to other muscle distinction is hands on in its a of results and agreed upon the visits. Our goal continues are we identify treatment(s) intinued working with Contrain CROs are companies that structure focused on drug did ID2B is very rare. An importease, the lack of knowledge, and the high cost of genetic program using new low cost cases all at once. Consequence all interested in finding the tient by 60% and we found	lude relevant statistical information produced, etc. entific advances and collabsorders, degenerative disepproach to funding. We claim to be to fund all possible to be to fund all possible to they are able to avail the tot can be determined to the degree of the fundations to serve the drug developmiscovery, such as robotic ant goal of the Foundation regarding the need for go to analysis has made this statement of the fundations are sequencing technology in the fundation of the	poration have a broader eases of tissues other losely monitor progress rly detail oriented approaches to a cure themselves of it Contract (CROs) as an integral ment industry and in is to identify LGMD2B enetic analysis on the process laborious and to diagnose not just our development of a program This program entients in the same	·
st the foundation's four largest direct charitable a ganizations and other beneficiaries served, confeinable to human health through their rethan muscle, and normal aging. The Foundation is impact on human health through their rethan muscle, and normal aging. The Foundation is impact on human health through their rethan muscle, and normal aging. The Foundation is impact on human health through their rethan muscle, and normal aging. The Foundation is impact on human health through their rethan muscle, and normal aging. The Foundation is impact on fearing the foundations in 2017 we compart of our therapy development progration is provided specialized knowledge and infrational provided specialized knowledge and infrational provided in the patients and physicians costly. In 2014 we launched a diagnosis specific disease but 34 other similar diseconsortium of family foundations that are reduced the price of diagnosing each paramount of time. This particular diagnost individuals with some form of muscular.	ctivities during the tax year Incrences convened, research pape is LGMD2B, the resulting scielevance to other muscle disindation is hands on in its a of results and agreed upon the visits. Our goal continues are we identify treatment(s) attinued working with Contra m CROs are companies that structure focused on drug did to the lack of knowledge, and the high cost of genetic program using new low cost and the lack of knowledge all interested in finding the tient by 60% and we found the program ended in August dystrophy were evaluated of	lude relevant statistical information produced, etc. entific advances and collabsorders, degenerative disepproach to funding. We claim to be to fund all possible to be to fund all possible so they are able to avail the tot color to the disease of the foundations to serve the drug developmiscovery, such as robotic and goal of the Foundation regarding the need for go to analysis has made this statement to the foundation of t	poration have a broader eases of tissues other losely monitor progress rly detail oriented approaches to a cure themselves of it Contract (CROs) as an integral ment industry and in is to identify LGMD2B enetic analysis on the process laborious and to diagnose not just our development of a program This program entents in the same lore than 2300 2% (~759) rec	·
Part IX-A  Summary of Direct Ch st the foundation's four largest direct charitable a ganizations and other beneficiaries served, confei  1 While the focus of the Jain Foundation is impact on human health through their ri than muscle, and normal aging. The Fou of every project we fund and keep track conference calls with researchers and si and have the patients diagnosed for who Research Organizations. In 2017 we cor part of our therapy development progra provide specialized knowledge and infra.  2 Patient Recruitment and Diagnosis. LGM patients worldwide. The rarity of the dis part of both the patients and physicians costly. In 2014 we launched a diagnosis specific disease but 34 other similar dise consortium of family foundations that ar reduced the price of diagnosing each pa amount of time. This particular diagnost individuals with some form of muscular.  3 Clinical Outcome Study. Clinical trials fri sensitive enough to measure a small be outcomes for dysferlinopathy so that we 2012. While the Jain Foundation is fund Newcastle, UK and a grant for the statis Foundation continues to lead and manag Japan and Australia) and involves the air	ctivities during the tax year Incrences convened, research pape is LGMD2B, the resulting scielevance to other muscle disindation is hands on in its a of results and agreed upon te visits. Our goal continues in we identify treatment(s) attituded working with Contram CROs are companies that structure focused on drug did to the high cost of genet program using new low cost eases all at once. Consequence all interested in finding the tient by 60% and we found the program using new founded to program ended in August dystrophy were evaluated dequently fail because testable in the firm the treatment or a can become trial ready, we might be study that tical analysis of the data to ge the study on a daily basis analysis of approximately 200	lude relevant statistical informing produced, etc. entific advances and collable sorders, degenerative disepproach to funding. We claim to be to fund all possible so they are able to avail to to be to fund all possible so they are able to avail to to Research Organizations to serve the drug developmiscovery, such as robotic and goal of the Foundation regarding the need for goal to the to the to the total to the temporation and the times are also led the temporation and the times more LGMD2B particles and the times are not well of the times are not well also being delivered. To for all all to the total to the t	nation such as the number of coration have a broader eases of tissues other losely monitor progress rly detail oriented approaches to a cure themselves of it Contract is (CROs) as an integral ment industry and  In is to identify LGMD2B enetic analysis on the process laborious and to diagnose not just our development of a program This program attents in the same ener than 2300 (2% (~759) rec defined and are not find measurable ome Study (COS) in late by and Dr Volker Straub, hington, DC, the Jain enters (in the US, Europe, m dysferlinopathy The	775,361
Part IX-A Summary of Direct Chest the foundation's four largest direct charitable a ganizations and other beneficiaries served, conference on human health through their rethan muscle, and normal aging. The Foundation is impact on human health through their rethan muscle, and normal aging. The Foundation of every project we fund and keep track conference calls with researchers and signand have the patients diagnosed for whe Research Organizations. In 2017 we compart of our therapy development prograp provide specialized knowledge and infra.  2 Patient Recruitment and Diagnosis. LGM patients worldwide. The rarity of the dispart of both the patients and physicians costly. In 2014 we launched a diagnosis specific disease but 34 other similar disconsortium of family foundations that air reduced the price of diagnosing each paamount of time. This particular diagnost individuals with some form of muscular.  3 Clinical Outcome Study. Clinical trials frosensitive enough to measure a small be outcomes for dysferlinopathy so that we 2012. While the Jain Foundation is funding Newcastle, UK and a grant for the statis Foundation continues to lead and managiapan and Australia) and involves the air study involves 6-8 clinic visits over 3-5 MRI/MRS assessments, as well as the content of the statis foundation is sufficient to the statis foundation.	ctivities during the tax year Incrences convened, research pape is LGMD2B, the resulting screelevance to other muscle distinction is hands on in its a of results and agreed upon the visits. Our goal continues are we identify treatment(s) intinued working with Contram CROs are companies that structure focused on drug did ID2B is very rare. An importease, the lack of knowledge, and the high cost of genet program using new low costs all at once. Consequent all interested in finding the tell to be 60% and we found the program ended in August dystrophy were evaluated dequently fail because testable in the study through the study of the study through the study on a daily basis analysis of approximately 200 years for each patient. Each ollection of biological samples	iude relevant statistical information produced, etc. entific advances and collabsorders, degenerative disepproach to funding. We claim timelines through quarters to be to fund all possible to be to fund all possible so they are able to avail to the Research Organizations to serve the drug developmiscovery, such as robotic ant goal of the Foundation regarding the need for goal canalysis has made this stock sequencing technology in the following the program and 32 to 2017. In this program and 32 to a cough a grant to Dr. Bushi Dr. Jacobs at CNMC, Was so COS is running at 15 ce of individuals suffering from the for banking. The	nation such as the number of coration have a broader eases of tissues other losely monitor progress rly detail oriented approaches to a cure themselves of it Contract (CROs) as an integral ment industry and control of the process laborious and to diagnose not just our development of a corogram This program attents in the same lore than 2300 (2% (~759) rec defined and are not find measurable ome Study (COS) in late by and Dr Volker Straub, hington, DC, the Jain enters (in the US, Europe, m dysferlinopathy The hysiotherapy, and	775,361 205,406
Part IX-A  Summary of Direct Ch st the foundation's four largest direct charitable a ganizations and other beneficiaries served, confei  1 While the focus of the Jain Foundation is impact on human health through their in than muscle, and normal aging. The Foundation of every project we fund and keep track conference calls with researchers and si and have the patients diagnosed for who Research Organizations. In 2017 we con part of our therapy development progra provide specialized knowledge and infra.  2 Patient Recruitment and Diagnosis. LGM patients worldwide. The rarity of the dis part of both the patients and physicians costly. In 2014 we launched a diagnosis specific disease but 34 other similar dise consortium of family foundations that ar reduced the price of diagnosing each pa amount of time. This particular diagnost individuals with some form of muscular.  3 Clinical Outcome Study. Clinical trials fri sensitive enough to measure a small be outcomes for dysferlinopathy so that we 2012. While the Jain Foundation is fundi Newcastle, UK and a grant for the statis Foundation continues to lead and manag Japan and Australia) and involves the ai study involves 6-8 clinic visits over 3-5 MRI/MRS assessments, as well as the co	ctivities during the tax year Incrences convened, research pape is LGMD2B, the resulting scielevance to other muscle disindation is hands on in its a of results and agreed upon te visits. Our goal continues are we identify treatment(s) attinued working with Contram CROs are companies that structure focused on drug did ID2B is very rare. An importease, the lack of knowledge, and the high cost of genet program using new low costs as all at once. Consequenteall interested in finding that the total to be determined to example the study of the study that the study of the st	iude relevant statistical informas produced, etc entific advances and collabsorders, degenerative dise pproach to funding. We cl timelines through quarte to be to fund all possible so they are able to avail to ct Research Organizations t serve the drug developmiscovery, such as robotic cant goal of the Foundation regarding the need for go ic analysis has made this st sequencing technology in the program and 32 in this program and 32 ile outcomes are not well drug being delivered. To fe el alunched a Clinical Outco rough a grant to Dr. Bushi Dr. Jacobs at CNMC, Was so COS is running at 15 ce of individuals suffering from visit includes medical, phes for banking. T entify and fund the develo field. The Foundation is a ability of which slows down of the art technologies at R lines that are useful to st el breeding facility at Jacks and to the foundation of the collegions of the collegions of the art technologies at R lines that are useful to st el breeding facility at Jacks and the collegions and the develor field.	nation such as the number of poration have a broader eases of tissues other losely monitor progress rly detail oriented approaches to a cure themselves of it Contract is (CROs) as an integral ment industry and  In is to identify LGMD2B enetic analysis on the process laborious and to diagnose not just our development of a program This program extents in the same ener than 2300 (2% (~759) rec defined and are not find measurable ome Study (COS) in late by and Dr Volker Straub, hington, DC, the Jain enters (in the US, Europe, in dysferlinopathy The hysiotherapy, and proment of research tools iso committed to in research In 2016, we Rockefeller University and the disease Finally, son Laboratories (Maine,	775,361 205,406
Part IX-A  Summary of Direct Ch st the foundation's four largest direct charitable a ganizations and other beneficiaries served, confei  While the focus of the Jain Foundation is impact on human health through their ri than muscle, and normal aging. The Fou of every project we fund and keep track conference calls with researchers and si and have the patients diagnosed for whi Research Organizations. In 2017 we con part of our therapy development progra provide specialized knowledge and infra.  Patient Recruitment and Diagnosis. LGM patients worldwide. The rarity of the dis part of both the patients and physicians costly. In 2014 we launched a diagnosis specific disease but 34 other similar dise consortium of family foundations that ar reduced the price of diagnosing each pa amount of time. This particular diagnost individuals with some form of muscular.  Clinical Outcome Study. Clinical trials fri sensitive enough to measure a small be outcomes for dysferlinopathy so that we 2012. While the Jain Foundation is fund Newcastle, UK and a grant for the statis Foundation continues to lead and mana; Japan and Australia) and involves the ai study involves 6-8 clinic visits over 3-5 MRI/MRS assessments, as well as the co.  Tools for Researchers. The Jain Foundat and resources that are needed to advan developing and providing frequently req began working with researchers to deve This work continued into 2017. In additi we continue to maintain large colonies of US) for use in dysferlin related research through e-mails and through the Founda- from selected patients, carriers and con-	ctivities during the tax year Incrences convened, research pape is LGMD2B, the resulting screelevance to other muscle distribution is hands on in its a of results and agreed upon the visits. Our goal continues are we identify treatment(s) attinued working with Contra mick CROs are companies that structure focused on drug did ID2B is very rare. An importease, the lack of knowledge, and the high cost of genet program using new low cost asses all at once. Consequent and incompanies that the cost of genet program using new low cost asses all at once. Consequent in the cost of genet program using new low cost asses all at once. Consequent in the cost of genet program using new low cost asses all at once. Consequent in the companies of the study of the cost of genet program ended in August dependently fail because testable the from the treatment or a can become trial ready, we may see the study on a daily basis of approximately 20% years for each patient. Each office the study on a daily basis of approximately 20% years for each patient. Each office research in the dysferlin uired reagents, the unavailation on continued to actively idea to con, we built a library of cell of mice at the custom mouse. Information about these reations website. In 2017, we trois that are now publicly attributed in the custom of the custom stroids and the custom mouse.	lude relevant statistical information produced, etc. entific advances and collabsorders, degenerative disepproach to funding. We claim to be to fund all possible to be to fund all possible to the fund development of the fundation of the f	poration have a broader eases of tissues other losely monitor progress rly detail oriented approaches to a cure themselves of it Contracts (CROs) as an integral ment industry and  In is to identify LGMD2B enetic analysis on the process laborious and to diagnose not just our development of a program. This program attents in the same lore than 2300 (2% (~759) rec. defined and are not find measurable lome Study (COS) in late by and Dr. Volker Straub, hington, DC, the Jain enters (in the US, Europe, m. dysferlinopathy. The hysiotherapy, and laboratories (Maine, son Laboratories (Maine, to relevant researchers.)	775,361 205,406
st the foundation's four largest direct charitable a rganizations and other beneficiaries served, conference on human health through their rights than muscle, and normal aging. The Foundation is impact on human health through their rights than muscle, and normal aging. The Foundation is impact on human health through their rights than muscle, and normal aging. The Foundation of every project we fund and keep track conference calls with researchers and is and have the patients diagnosed for who were recommended in the patients. In 2017, we compart of our therapy development prograp provide specialized knowledge and infra.  2 Patient Recruitment and Diagnosis. LGM patients worldwide. The rarity of the dispart of both the patients and physicians costly. In 2014 we launched a diagnosis specific disease but 34 other similar disconsortium of family foundations that arreduced the price of diagnosing each palamount of time. This particular diagnost individuals with some form of muscular.  3 Clinical Outcome Study. Clinical trials frosensitive enough to measure a small be outcomes for dysferlinopathy so that we 2012. While the Jain Foundation is funding Newcastle, UK and a grant for the statis Foundation continues to lead and managuapan and Australia) and involves the air study involves 6-8 clinic visits over 3-5. MRI/MRS assessments, as well as the continue to maintain large colonies of the proposition of the statis of the stati	ctivities during the tax year Incrences convened, research pape is LGMD2B, the resulting scielevance to other muscle disindation is hands on in its a of results and agreed upon te visits Our goal continues an weidentify treatment(s) attinued working with Contram CROs are companies that structure focused on drug did ID2B is very rare. An importease, the lack of knowledge, and the high cost of genetic program using new low costs as all at once. Consequenter all interested in finding the title to the contraction of the treatment of the contraction of the study through the title from the treatment of the can become trial ready, we may the bulk of the study through the study on a daily basis analysis of approximately 200 years for each patient. Each office research in the dysferlin uired reagents, the unavailation on the contraction of biological samples on, we built a library of cell of mice at the custom mouse. Information about these reations website. In 2017, we trols that are now publicly and received in the study that are now publicly and received in the study that are now publicly and received in the custom mouse. Information about these reations website. In 2017, we trols that are now publicly and received in the study that are now publicly and received in the study that are now publicly and received in the study that are now publicly and received in the study that are now publicly and received in the study that are now publicly and received in the study that are now publicly and received in the study that are now publicly and received in the study that are now publicly and received in the study that are now publicly and received in the study that are now publicly and received in the study that are now publicly and received in the study that are now publicly and received in the study that are now publicly and received in the study that the study	illude relevant statistical information produced, etc. entific advances and collabsorders, degenerative disepproach to funding. We clutimelines through quarters to be to fund all possible to be to fund all possible so they are able to avail to the Research Organizations to serve the drug developmiscovery, such as robotic ant goal of the Foundation regarding the need for goal canalysis has made this stockness to sequencing technology in the second produced the learn patients through our patients to be allowed a Clinical Outcomes are not well of allowed a Clinical Outcomes are not well and the grant to Dr. Bushi Dr. Jacobs at CNMC, Was so COS is running at 15 cellowed a grant to Dr. Bushi Dr. Jacobs at CNMC, Was so COS is running at 15 cellowed a Clinical Outcomes are not well and the development of the patients of the produced the development of the patients of the	poration have a broader eases of tissues other losely monitor progress rly detail oriented approaches to a cure themselves of it Contract is (CROs) as an integral ment industry and  In is to identify LGMD2B enetic analysis on the process laborious and to diagnose not just our development of a program This program sitients in the same fore than 2300 (2% (~759) rec defined and are not find measurable ome Study (COS) in late by and Dr Volker Straub, hington, DC, the Jain enters (in the US, Europe, in dysferlinopathy The hysiotherapy, and proposed for the process of the process of the US, Europe, in dysferlinopathy The hysiotherapy, and proment of research tools lso committed to in research In 2016, we Rockefeller University and the disease Finally, son Laboratories (Maine, to relevant researchers ent of several iPS cells	775,361 205,406 95,711
st the foundation's four largest direct charitable a rganizations and other beneficiaries served, confein the focus of the Jain Foundation is impact on human health through their ruthan muscle, and normal aging. The Foundation is impact on human health through their ruthan muscle, and normal aging. The Foundation of every project we fund and keep track conference calls with researchers and smand have the patients diagnosed for which Research Organizations. In 2017 we compart of our therapy development prograp provide specialized knowledge and infration 2 Patient Recruitment and Diagnosis. LGM patients worldwide. The rarity of the dispart of both the patients and physicians costly. In 2014 we launched a diagnosis specific disease but 34 other similar disconsortium of family foundations that arreduced the price of diagnosing each patients and involudials with some form of muscular.  3 Clinical Outcome Study. Clinical trials frosensitive enough to measure a small be outcomes for dysferlinopathy so that we 2012. While the Jain Foundation is fund. Newcastle, UK and a grant for the statis Foundation continues to lead and managuapan and Australia) and involves the arstudy involves 6-8 clinic visits over 3-5. MRI/MRS assessments, as well as the continue to maintain large colonies of the search through emails and through the Foundation endition of the search through emails and through the Foundation selected patients, carriers and conforms selected patients, carriers and conforms and conforms selected patients, carriers and conforms.	ctivities during the tax year Incrences convened, research pape is LGMD2B, the resulting scielevance to other muscle disindation is hands on in its a of results and agreed upon te visits. Our goal continues are we identify treatment(s) attinued working with Contram CROs are companies that structure focused on drug did ID2B is very rare. An importease, the lack of knowledge, and the high cost of genetic program using new low costs as all at once. Consequent all interested in finding that the total to be equently fail because testable in the study that the study of the study that the study on a daily basis analysis of the data to get the study on a daily basis analysis of approximately 200 years for each patient. Each of since in the dysferlin uired reagents, the unavailation and the cost of the study in the study of cell of mice at the custom mouse. Information about these reations website. In 2017, we trois that are now publicly are ments made by the foundation of us. Therapeutics for the purpose.	illude relevant statistical information produced, etc. entific advances and collabsorders, degenerative disepproach to funding. We clutimelines through quarters to be to fund all possible so they are able to avail to the serve the drug developmiscovery, such as robotic ant goal of the Foundation regarding the need for goal analysis has made this st sequencing technology in the serve the drug developmiscovery, such as robotic ant goal of the Foundation regarding the need for goal analysis has made this st sequencing technology in the sequencing technologies at sequencing delivered. To see a launched a Clinical Outcome to the sequencing delivered to sequence and the sequencing at 15 cecond in the sequencing from a visit includes medical, presenting from a sequencing from a visit includes medical, presenting and fund the development of the sequencing facility at Jacksesources is disseminated to complete the development of the sequencing facility at Jacksesources is disseminated to complete the development of the sequencing facility at Jacksesources is disseminated to complete the development of the sequencing facility at Jacksesources is disseminated to complete the development of the sequencing facility at Jacksesources is disseminated to complete the development of the sequencing facility at Jacksesources is disseminated to complete the development of the sequencing facility at Jacksesources is disseminated to complete the development of the sequencing facility at Jacksesources is disseminated to complete the development of the sequencing facility at Jacksesources is disseminated to complete the development of the sequencing facility at Jacksesources is disseminated to complete the development of the sequencing facility at Jacksesources is disseminated to complete the development of the sequencing facility at Jacksesources is disseminated to complete the development of the sequencing facility at Ja	poration have a broader eases of tissues other losely monitor progress rly detail oriented approaches to a cure themselves of it Contract is (CROs) as an integral ment industry and  In is to identify LGMD2B enetic analysis on the process laborious and to diagnose not just our development of a program This program attents in the same fore than 2300 2% (~759) rec defined and are not find measurable ome Study (COS) in late by and Dr Volker Straub, hington, DC, the Jain enters (in the US, Europe, in dysferlinopathy The hysiotherapy, and promested to in research 1 2016, we cockefeller University and the disease Finally, son Laboratories (Maine, to relevant researchers ent of several iPS cells	775,361 205,406 95,711 376,075
18t the foundation's four largest direct charitable a rganizations and other beneficiaries served, conference calls with researchers and significant property project we fund and keep track conference calls with researchers and significant provides peculiar and have the patients diagnosed for whe Research Organizations. In 2017 we corport of our therapy development prograprovide specialized knowledge and infra.  2 Patient Recruitment and Diagnosis. LGM patients worldwide. The rarity of the dispart of both the patients and physicians costly. In 2014 we launched a diagnosis specific disease but 34 other similar disconsortium of family foundations that arreduced the price of diagnosing each patients with some form of muscular.  3 Clinical Outcome Study. Clinical trials from sensitive enough to measure a small be outcomes for dysferlinopathy so that we 2012. While the Jain Foundation is fundin Newcastle, UK and a grant for the statis Foundation continues to lead and managiapan and Australia) and involves the air study involves 6-8 clinic visits over 3-5 MRI/MRS assessments, as well as the continue to maintain large colonies of the Statis work continued into 2017. In additive continue to maintain large colonies of US) for use in dysferlin related research through e-mails and through the Foundation selected patients, carriers and continued the two largest program-related investives availability of treatments and cures for largest program-related investive availability of treatments and cures for largest program-related investives.	ctivities during the tax year Incrences convened, research paper and tax year Incrences convened, research paper and tax year Incrences and agreed upon the visits Our goal continues and we identify treatment(s) attituded working with Contra man CROs are companies that structure focused on drug did ID2B is very rare. An importence, the lack of knowledge, and the high cost of genetic program using new low conceases all at once. Consequenter all interested in finding that the tax years and years for each patient of the can become trial ready, we may the bulk of the study that tical analysis of the data to get the study on a daily basis of approximately 200 years for each patient. Each collection of biological sample into continued to actively idea to expect the study of a daily basis of approximately 200 years for each patient. Each collection of biological sample into continued to actively idea to expect the study of a daily basis of approximately 200 years for each patient. Each collection of biological sample into continued to actively idea to expect the study of a daily basis of approximately 200 years for each patient. Each collection of biological sample into continued to actively idea to expect the study of a daily basis of approximately 200 years for each patient. Each collection of biological sample into continued to actively idea to the study of a daily basis of approximately 200 years for each patient. Each collection of biological sample into continued to actively idea to the study of a daily basis of approximately 200 years for each patient. Each collection of biological sample into the service of the study of the stud	illude relevant statistical information produced, etc. entific advances and collabsorders, degenerative disepproach to funding. We clutimelines through quarters to be to fund all possible so they are able to avail to the serve the drug developmiscovery, such as robotic ant goal of the Foundation regarding the need for goal analysis has made this st sequencing technology in the serve the drug developmiscovery, such as robotic ant goal of the Foundation regarding the need for goal analysis has made this st sequencing technology in the sequencing technologies at sequencing delivered. To see a launched a Clinical Outcome to the sequencing delivered to sequence and the sequencing at 15 cecond in the sequencing from a visit includes medical, presenting from a sequencing from a visit includes medical, presenting and fund the development of the sequencing facility at Jacksesources is disseminated to complete the development of the sequencing facility at Jacksesources is disseminated to complete the development of the sequencing facility at Jacksesources is disseminated to complete the development of the sequencing facility at Jacksesources is disseminated to complete the development of the sequencing facility at Jacksesources is disseminated to complete the development of the sequencing facility at Jacksesources is disseminated to complete the development of the sequencing facility at Jacksesources is disseminated to complete the development of the sequencing facility at Jacksesources is disseminated to complete the development of the sequencing facility at Jacksesources is disseminated to complete the development of the sequencing facility at Jacksesources is disseminated to complete the development of the sequencing facility at Jacksesources is disseminated to complete the development of the sequencing facility at Jacksesources is disseminated to complete the development of the sequencing facility at Ja	poration have a broader eases of tissues other losely monitor progress rly detail oriented approaches to a cure themselves of it Contract is (CROs) as an integral ment industry and  In is to identify LGMD2B enetic analysis on the process laborious and to diagnose not just our development of a program This program attents in the same fore than 2300 2% (~759) rec defined and are not find measurable ome Study (COS) in late by and Dr Volker Straub, hington, DC, the Jain enters (in the US, Europe, in dysferlinopathy The hysiotherapy, and promested to in research 1 2016, we cockefeller University and the disease Finally, son Laboratories (Maine, to relevant researchers ent of several iPS cells	775,361 205,406 95,711

Expenses, contributions, gifts, etc —total from Part I, column (d), line 26. . . . . . . . . . . .

Amounts paid to acquire assets used (or held for use) directly in carrying out charitable, etc.,

Foundations that qualify under section 4940(e) for the reduced rate of tax on net investment

Adjusted qualifying distributions. Subtract line 5 from line 4. . . . . . . . . .

Amounts set aside for specific charitable projects that satisfy the

the section 4940(e) reduction of tax in those years

2

3

4

5

Qualifying distributions. Add lines 1a through 3b Enter here and on Part V, line 8, and Part XIII, line 4

Note: The amount on line 6 will be used in Part V, column (b), in subsequent years when calculating whether the foundation qualifies for

1a

1b

2

3a 3h

4

5

4,367,676

4.567.676

4,567,676

Form **990-PF** (2017)

200,000

a From 2012. . .

d From 2015. .

**b** From 2013. . . . c From 2014. .

e From 2016. . . . .

indicated below:

a Corpus Add lines 3f, 4c, and 4e Subtract line 5 b Prior years' undistributed income Subtract line 4b from line 2b . . . . . . . . . . . . c Enter the amount of prior years' undistributed income for which a notice of deficiency has been issued, or on which the section 4942(a) tax has been previously assessed. . . . . . d Subtract line 6c from line 6b Taxable amount e Undistributed income for 2016 Subtract line 4a from line 2a Taxable amount—see instructions . . . . . . . f Undistributed income for 2017 Subtract lines 4d and 5 from line 1. This amount must be distributed in 2018 . . . . . 7 Amounts treated as distributions out of corpus to satisfy requirements imposed by section 170(b)(1)(F) or 4942(g)(3) (Election may be required - see instructions) . . . . . . . . . 8 Excess distributions carryover from 2012 not

applied on line 5 or line 7 (see instructions) . . .

Subtract lines 7 and 8 from line 6a . . . . . .

9 Excess distributions carryover to 2018.

10 Analysis of line 9

a Excess from 2013. . .

c Excess from 2015. . . .

d Excess from 2016. . .

e Excess from 2017. . .

**b** Excess from 2014. .

Page 9

37,508

1,237,508

Form **990-PF** (2017)

## Undistributed Income (see instructions) Part XIII

	olidistributed Income (see instruct	LIUIIS			
		(a) Corpus	(b) Years prior to 2016	<b>(c)</b> 2016	<b>(d)</b> 2017
1	Distributable amount for 2017 from Part XI, line 7				1,23
2	Undistributed income, if any, as of the end of 2017				
а	Enter amount for 2016 only				
b	Total for prior years 20 , 20 , 20				
3	Excess distributions carryover, if any, to 2017				

1.950.684 2,703,379 4.525.947

3.644.614 3,611,020

f Total of lines 3a through e. . . . . . .

4 Qualifying distributions for 2017 from Part XII, line 4 🕨 \$ a Applied to 2016, but not more than line 2a **b** Applied to undistributed income of prior years (Election required—see instructions). . . . .

c Treated as distributions out of corpus (Election

required—see instructions). . . . . . . . . **d** Applied to 2017 distributable amount. . . .

e Remaining amount distributed out of corpus

**5** Excess distributions carryover applied to 2017

(If an amount appears in column (d), the same amount must be shown in column (a) ) 6 Enter the net total of each column as

2.703.379

4,525,947

3,644,614

3,611,020

3.330.168

3,330,168


19,765,812

1.950.684

17,815,128

16.435.644

	m 990-PF (2017)					Page 10	
	Part XIV Private Operating Found	ations (see instr	uctions and Part \	VII-A, question 9)			
	If the foundation has received a ruling or de foundation, and the ruling is effective for 20	17, enter the date	of the ruling.	▶∟_			
b	Check box to indicate whether the organization is a private operating foundation described in section 4942(j)(3) or 4942(j)(5)						
<b>2</b> a	Enter the lesser of the adjusted net	Tax year		Prior 3 years		(e) Total	
	income from Part I or the minimum investment return from Part X for each	(a) 2017	<b>(b)</b> 2016	(c) 2015	(d) 2014	(e) Iotai	
	year listed						
b	85% of line 2a						
С	Qualifying distributions from Part XII, line 4 for each year listed						
d	Amounts included in line 2c not used directly for active conduct of exempt activities						
e	Qualifying distributions made directly for active conduct of exempt activities Subtract line 2d from line 2c						
3	Complete 3a, b, or c for the alternative test relied upon						
а	"Assets" alternative test—enter						
	(1) Value of all assets						
	(2) Value of assets qualifying under section 4942(j)(3)(B)(i)						
b	"Endowment" alternative test— enter 2/3 of minimum investment return shown in Part X, line 6 for each year listed						
С	"Support" alternative test—enter						
	(1) Total support other than gross investment income (interest, dividends, rents, payments						
	on securities loans (section 512(a)(5)), or royalties)						
	(2) Support from general public						
	and 5 or more exempt organizations as provided in section 4942(j)(3)(B)(iii)						
	(3) Largest amount of support from an exempt organization						
	(4) Gross investment income						
Pa	Supplementary Information			organization ha	d \$5,000 or mor	e in	
_	assets at any time during th Information Regarding Foundation Man		tructions.)				
	List any managers of the foundation who have before the close of any tax year (but only if	e contributed more they have contribut	ted more than \$5,00	0) (See section 507	'(d)(2) )	on	
b	List any managers of the foundation who ow ownership of a partnership or other entity)				arge portion of the		
	ownership of a partnership of other entity) (	or which the founda	dominas a 10 % or gr	reater interest			
2	Information Regarding Contribution, Gr	ant, Gift, Loan, Sc	holarship, etc., Pr	ograms:			
	Check here ▶ ☐ If the foundation only mak unsolicited requests for funds If the founda other conditions, complete items 2a, b, c, a	tion makes gifts, gr				nder	
a	The name, address, and telephone number of	or e-mail address of	f the person to whon	n applications should	be addressed		
	The Jain Foundation Inc 9725 Third Avenue NE Ste 204						
	Seatlle, WA 98115 (425) 882-1492						
_	See Foundation Website www jain-foundation						
b	The form in which applications should be sul		ation and materials t	they should include			
_	See Foundation Website www jain-foundation	n org					
C	Any submission deadlines						
_	There are no application deadlines						
d	Any restrictions or limitations on awards, su factors	,	·	·	·		
	The explicit goal of the Jain Foundation is to not have application to this disease will not		ent of a treatment o	or cure for LGMD2B/N	1ıyoshı Any propose	ed project that does	



Form 990-PF (2017)	A -41: -141				Page <b>1</b> 2
Part XVI-A Analysis of Income-Producing	Activities		1		
Enter gross amounts unless otherwise indicated	Unrelated business income		Excluded by section 512, 513, or 514		(e) Related or exempt
Program service revenue	(a) Business code	(b) Amount	(c) Exclusion code	(d) Amount	function income (See instructions )
a					
b					
c					
d e					
f					
g Fees and contracts from government agencies					
2 Membership dues and assessments					
3 Interest on savings and temporary cash			.,	4.04.5	
Investments			14	4,815	
5 Net rental income or (loss) from real estate					
a Debt-financed property					
<b>b</b> Not debt-financed property					
6 Net rental income or (loss) from personal property					
7 Other investment income					
<b>8</b> Gain or (loss) from sales of assets other than inventory					4,047,712
9 Net income or (loss) from special events					, , , , , , ,
10 Gross profit or (loss) from sales of inventory					
11 Other revenue					
a <u>Unused Grant Funds Return</u> b			21	36,139	
c					
d					
e					
12 Subtotal Add columns (b), (d), and (e)				40,954	
<b>13 Total.</b> Add line 12, columns (b), (d), and (e)			1	.3	4,088,666
(See worksheet in line 13 instructions to verify calcular Part XVI-B Relationship of Activities to the		ment of Evem	nt Purnoses		
Explain below how each activity for which			<u> </u>	uted importantly to	
the accomplishment of the foundation's ex	empt purposes	other than by pro	viding funds for such	n purposes) (See	
instructions )					
				Fo	rm <b>990-PF</b> (2017)

orm	990-P	F (2017)						Pa	ge <b>13</b>
Par	t XV	Information Re Exempt Organi		fers To and Transact	ions and R	elationships With Nonchari	table		
				any of the following with lizations) or in section 527		anızatıon described in section 501 political organizations?		Yes	No
a Tr	ansfer	s from the reporting four	dation to a noncha	arıtable exempt organızatı	on of				
(1	L) Ca	sh					1a(1)		No
(2	2) Oth	ner assets					1a(2)		No
<b>b</b> 0	ther tr	ansactions							
•	•	es of assets to a nonchar					1b(1)		No
•	•	chases of assets from a r					1b(2)		No
•	•	ntal of facilities, equipmei Imbursement arrangemer	•				1b(3) 1b(4)		No No
•	•	ans or loan quarantees.					1b(5)		No
•	•	-		draising solicitations.			1b(6)		No
•	•			assets, or paid employees			1c		No
	any ti		ngement, show in		he goods, oth	received less than fair market valuer assets, or services received ription of transfers, transactions, and sha		ngemen	ts
. ,		<b>(-,</b>	(-,		(=/=====	,			
<u> </u>				1.1.11					
de	escribe	,	Code (other than	n, or related to, one or mo section 501(c)(3)) or in s		3	☐Yes	✓	No
		(a) Name of organization		(b) Type of organiz	ation	(c) Description of relati	onship		
	1	-d	T 4-1 T 1					L _ LI .	h
	ان ا	naer penalties of perjury,	i deciare that I ha	ive examined this return, i	nciuaing acco	mpanying schedules and statemer	its, and	to the	pest

2a Is the foundation directly or indirectly affiliated with, or related to, one or more tax-exempt organizations described in section 501(c) of the Code (other than section 501(c)(3)) or in section 527?									
<b>b</b> If "Yes," complete the following schedule									
(a) Name of organization	(b) Type of organization	(c) Description of relationship							
		ompanying schedules and statements, and to the best							

Sign

## of my knowledge and belief, it is true, correct, and complete Declaration of preparer (other than taxpayer) is based on all information of which preparer has any knowledge May the IRS discuss this 2018-11-06 with the preparer shown Signature of officer or trustee Date Title (see instr )? 🗹 Yes 🗆 No Print/Type preparer's name Preparer's Signature Date PTIN

Here Paid

Lorraine S Boss Esq **Preparer** LEXINGTON TAX SERVICES Firm's name ▶ **Use Only** Firm's address ▶ 1325 FRANKLIN AVE STE 335 GARDEN CITY, NY 115301604

Check if selfemployed ▶ 🗌

Phone no (516) 739-5151

P01450835

Fırm's EIN ▶11-3538932

Form 990PF Part VIII Line 1 - List all officers, directors, trustees, foundation managers and their compensation (a) Name and address Title, and average (c) Compensation (If (d) Expense account, hours per week not paid, enter Contributions to (e) other allowances (b) devoted to position -0-) employee benefit plans and deferred compensation Dr Plavi Mittal 61,500 5,167 Pres 1/17-4/17 50 00 9725 Third Avenue NE Ste 204 Seattle, WA 98117 Ajıt Jaın Director 3 00 Island Drive Rye, NY 10580

Indrima Jain	Director	0		
Island Drive Rye, NY 10580	1 00			
Akshay Jaın	CEO	12,500	12,500	
Island Drive	40 00			

Island Drive New York, NY 10580	40 00	, ,	,	
Ajay Jain	Director	0		
Island Drive Rye, NY 10580	1 00			
Doug Albrecht PhD	Co-President	121,415	12,500	

Ajay Jain	Director	0		
Island Drive Rye, NY 10580	1 00			
Doug Albrecht PhD	Co-President	121,415	12,500	
9725 Third Avenue NE Suite 20	40 00			

Rye, NY 10580				
Doug Albrecht PhD	Co-President	121,415	12,500	
9725 Third Avenue NE Suite 20 Third Avenue NE, WA 98117	40 00			

Doug Albrecht PhD	Co-President	121,415	12,500	
9725 Third Avenue NE Suite 20 Third Avenue NE, WA 98117	40 00			
Laura Rufibach PhD	Co-President	123,271	12,500	

40 00

9725 Third Avenue NE Suite 20

Seattle, WA 98117

Form 990PF Part XV Line 3 - Grants and Contributions Paid During the Year or Approved for Future Payment Recipient Foundation Purpose of grant or If recipient is an individual, Amount show any relationship to status of contribution any foundation manager recipient Name and address (home or business) or substantial contributor a Paid during the year Univof Wisconsin Madison-Dr KSonnem NONE PC Scientific Research Grant 142,416 1525 Linden Dr 333 Bock Labs Madison WI 53706

Madison, W1 55700				
Ohio State University Dr Weisleder 473 W 10th Ave Columbus, OH 43210	NONE	PC	Scientific Research Grant	98,808
Newcastle University-Dr Bushby 16/17 Framlington Place New Castle upon, Tyne NE2 4AB UK	NONE	NC	Natural History Project - Clinical Outcome Study	678,835

За

2,226,705

Recipient Foundation Purpose of grant or If recipient is an individual, Amount show any relationship to status of contribution any foundation manager recipient Name and address (home or business) or substantial contributor a Paid during the year MIT Dr Guarente NONE PC Scientific Research Grant 57.551 77 Massachusetts Avenue 68-280

Form 990PF Part XV Line 3 - Grants and Contributions Paid During the Year or Approved for Future Payment

Cambridge, MA 02139				
Emory Genetics Lab - Dr Madhuri Heg 2165 N Decatur Road Atlanta, GA 30033	NONE	PC	Scientific Research Grant	67,363
University of Maryland-Dr Robert Bl	NONE	PC	Scientific Research Grant	240.000

Atlanta, GA 30033				
University of Maryland-Dr Robert Bl 655 W Baltimore Street	NONE	PC	Scientific Research Grant	:
Paltimore MD 21201				

University of Maryland-Dr Robert Bl 655 W Baltimore Street Baltimore, MD 21201	NONE	PC	Scientific Research Grant	
Baltimore, MD 21201				

За

Total				2,226,705
655 W Baltimore Street Baltimore, MD 21201				
University of Maryland-Dr Robert Bl	NONE	PC	Scientific Research Grant	240,000

University of Maryland-Dr Robert Bl	NONE	PC	Scientific Research Grant	240,
655 W Baltimore Street Baltimore, MD 21201				

Form 990PF Part XV Line 3 - Grants and Contributions Paid During the Year or Approved for Future Payment Recipient Foundation Purpose of grant or If recipient is an individual, Amount show any relationship to status of contribution any foundation manager recipient Name and address (home or business) or substantial contributor a Paid during the year Childrens Research Instit Marni Jac NONE PC Scientific Research Grant 108,500 111 Michigan Avenue NW Suite 5400 Washington DC DC 20010

Washington De, De 20010				
Rockefeller University Drs Chait Ro 1230 York Avenue New York, NY 10065	NONE	PC	General Support	63,300
Childrens Hospital Westmead- DrCoop Locked Bag 4001 Westmead, Sydney 2145 AS	NONE	NC	Scientific Research Grant	3,075

2,226,705 Total . .

За

Form 990PF Part XV Line 3 - Grants and Contributions Paid During the Year or Approved for Future Payment Recipient If recipient is an individual, Foundation Purpose of grant or Amount show any relationship to contribution status of any foundation manager

Name and address (home or business)	or substantial contributor	recipione		
a Paid during the year				
Brigham and Women's Hospital Dr Kel 101 Huntington Ave	NONE	PC	Scientific Research Grant	79,672

recipient

Boston, MA 02199				
University of Illinois - Dr Koh 1919 W Taylor St 650 AHSB M/C994 Chicago, IL 60612	NONE	PC	Scientific Research Grant	

3a

University of Illinois - Dr Koh 1919 W Taylor St 650 AHSB M/C994 Chicago, IL 60612	NONE	PC	Scientific Research Grant	34,361
Columbia University622 W 113th Street	NONE	PC	General Support	100,000

Chicago, IL 60612				
Columbia University622 W 113th Street New York, NY 10025	NONE	PC	General Support	10

Chicago, IL 60612				
Columbia University622 W 113th Street New York, NY 10025	NONE	PC	General Support	100,

.nicago, IL 60612				
Columbia University622 W 113th Street lew York, NY 10025	NONE	PC	General Support	100,000

olumbia University622 W 113th Street	NONE	PC	General Support	100
ew York, NY 10025				

lew York, NY 10025			
Total		•	2 226 705

Form 990PF Part XV Line 3 - Grants and Contributions Paid During the Year or Approved for Future Payment Recipient If recipient is an individual, Foundation Purpose of grant or Amount show any relationship to contribution status of any foundation manager recipient Name and address (home or business) or substantial contributor

a Paid during the year				
Center for Advanced Molecular 194 Road 15 Sion Mumbai, Maharashtra 400022 IN	NONE	NC	Scientific Research Grant	52,235

IN				
Univ of British Columbia Dr Bernatc 103-6190 Agronomy Road Vancouver, British Columbia V6T 1Z3 CA	NONE	NC	Scientific Research Grant	69,236

П	103-6190 Agronomy Road Vancouver, British Columbia V6T 1Z3 CA	NONE	NC .	Scientific Research Grant	69,2
П	Wayne State Dr Drescher	NONE	PC	Scientific Research Grant	72,8

CA				
Wayne State Dr Drescher 1200 Lande MRB Detroit. MI 48202	NONE	PC	Scientific Research Grant	72,850

Wayne State Dr Drescher 1200 Lande MRB Detroit, MI 48202	NONE	PC	Scientific Research Grant	72,850
<b>-</b>	2 226 705			

Wayne State Dr Drescher 1200 Lande MRB Detroit, MI 48202	NONE	PC	Scientific Research Grant	72,
Total				2,226,705

3a

Recipient If recipient is an individual, Foundation Purpose of grant or Amount show any relationship to status of contribution any foundation manager recipient Name and address (home or business) or substantial contributor a Paid during the year D-C NIONE

Form 990PF Part XV Line 3 - Grants and Contributions Paid During the Year or Approved for Future Payment

300 Pasteur Drive Stanford, CA 94305	NONE	PC	Scientific Research Grant	66,925
Fondazione Santa Lucia Dr Puri Via Del Fosso di Fiorano 64 Rome 00143	NONE	NC	Scientific Research Grant	28,517

Fondazione Santa Lucia Dr Puri Via Del Fosso di Fiorano 64 Rome 00143 IT	NONE	NC	Scientific Research Grant	28,517
Hana Feiner-Scholarship Susquehanna 514 University Avenue Selinsgrove, PA 17870	NONE	I	IRS Approved Scholarship	3,000

Rome 00143				
Hana Feiner-Scholarship Susquehanna 514 University Avenue Selinsgrove, PA 17870	NONE	I	IRS Approved Scholarship	3,00

Hana Feiner-Scholarship Susquehanna 514 University Avenue Selinsgrove, PA 17870	NONE	I	IRS Approved Scholarship	3,000
IT				

<b>-</b>		 2 226 705
Selinsgrove, PA 17870		
514 University Avenue		

Selinsgrove, PA 17870		
Total	 	 2,226,705

Form 990PF Part XV Line 3 - Grants and Contributions Paid During the Year or Approved for Future Payment Recipient If recipient is an individual, Foundation Purpose of grant or Amount show any relationship to contribution status of any foundation manager recipient Name and address (home or business) or substantial contributor

a Paid during the year				
Duke University -Dr Bursac 100 Science Dr 1138 CIEMAS Durham, NC 27708	NONE	PC	Scientific Research Grant	70,000

Ourham, NC 27708				
Ohio State University Dr Weisleder 173 W 10th Ave Columbus, OH 43210	NONE	PC	Scientific Research Grant	13,39

Ohio State University Dr Weisleder 473 W 10th Ave Columbus, OH 43210	NONE	PC	Scientific Research Grant	13,395
University of Washington - Dr Baker Box 351655	NONE	PC	Scientific Research Grant	100,000

Coldinbus, Off 45210				
University of Washington - Dr Baker Box 351655 Seattle, WA 98195	NONE	PC	Scientific Research Grant	100,000

University of Washington - Dr Baker Box 351655 Seattle, WA 98195	NONE	PC	Scientific Research Grant	100,0
Total		•		2 226 705

Box 351655 Seattle, WA 98195		
Total	 ▶	2,226,705

Recipient Foundation Purpose of grant or If recipient is an individual, Amount show any relationship to status of contribution any foundation manager recipient Name and address (home or business) or substantial contributor a Paid during the year UT Southwestern Medical Center NONE PC Scientific Research Grant 66,666

Form 990PF Part XV Line 3 - Grants and Contributions Paid During the Year or Approved for Future Payment

Dallas, TX 75390				
Lauren Boyd - Scholarship UC Davis 120 Costanza Dr Martinez, CA 94553	NONE	I	IRS Approved Scholarship	3,000

Martinez, CA 94553				
Filipe Contaifer - Scholarship Texa 1512 Sugar Hill Lindale, TX 75771	NONE	I	IRS Approved Scholarship	3,0

3a

Filipe Contaifer - Scholarship Texa 1512 Sugar Hill Lindale, TX 75771	NONE	I	IRS Approved Scholarship	3,000
Total				2,226,705

Form 990PF Part XV Line 3 - Grants and Contributions Paid During the Year or Approved for Future Payment Recipient If recipient is an individual, Foundation Purpose of grant or Amount show any relationship to contribution status of any foundation manager recipient Name and address (home or business) or substantial contributor

a Paid during the year				
Catherine Hua - Scholarship Harvard 2608 Ave W	NONE	I	IRS Approved Scholarship	3,000
Brooklyn NV 11229				

aille Coombs -Scholarship Brigham 552 N Jullion Way oise, ID 83704	NONE	I	IRS Approved Scholarship	

3a

3652 N Jullion Way Boise, ID 83704	NONE	1	TRS Approved Scholarship	
Yuan Zhuan- Scholarshıp Unıv Washın	NONE	I	IRS Approved Scholarship	

Boise, ID 83704				
Yuan Zhuan- Scholarshıp Univ Washin 12367 SE 41st Ln	NONE	I	IRS Approved Scholarship	500
Pollovuo MA 00006				

500

Yuan Zhuan- Scholarship Univ Washin	NONE	I	IRS Approved Scholarship	500
12367 SE 41st Ln Bellevue, WA 98006				
20				

Total	l		•	2 226 705
12367 SE 41st Ln Bellevue, WA 98006			,	

efile GRAPHIC print - DO NOT F	ROCESS	As Filed D	ata -		DLN: 93491310012538
TY 2017 Accounting Fe	ees Sch	edule			
	Name:	The Jain	Foundation Inc		
	EIN:	20-0284	800		
<b>Software ID:</b> 17005038					
Software \	Version:	2017v2.2	2		
Accounting Fees Schedule					
Category	Amo	ount	Net Investment Income	Adjusted Net Income	t Disbursements for Charitable Purposes
Pradeep Agarwal, CPA		5,510		0	0 5,510

eine Graffite print - Do Not Process	ASTITIEU Data -	DEN. 95491510012550
TY 2017 Investments Corpora	te Stock Schedule	
Name:	The Jain Foundation Inc	
EIN:	20-0284800	
Software ID:	17005038	

DIN: 93491310012538

26,639,777

20,432,461

efile GRADHIC print - DO NOT PROCESS | As Filed Data -

134,395 Shares Berkshire Hathaway Inc.

<b>Software Version:</b> 2017v2.2		
Name of Stock	End of Year Book Value	End of Year Fair Market Value
	Value	Market Value

efile GRAPHIC print - DO NOT PROCESS	As Filed Data -	DLN: 93491310012538
TY 2017 Investments - Land 9	Schedule	
Name:	The Jain Foundation	Inc
EIN:	20-0284800	
Software ID:	17005038	
Coffee vous Vousions	20172	

Software Version: 2017v2.2					
Category/ Item	Cost/Other Basis	Accumulated Depreciation	Book Value	End of Year Fair Market Value	
Furniture and Fixtures	1,410		1,410	1,410	

efile GRAPHIC print - DO NOT PROCI	ESS As Filed Data	-	DLN	N: 93491310012538
TY 2017 Legal Fees Sched	ule			
Na	me: The Jain Fou	ındatıon Inc		
· ·	<b>EIN:</b> 20-0284800			
Software	<b>ID:</b> 17005038			
Software Vers	ion: 2017v2.2			
Category	Amount	Net Investment Income	Adjusted Net Income	Disbursements for Charitable Purposes
Foley Hoag, LLP	8,528	0	0	8,528

efile GRAPHIC print - DO NOT PROCESS	As Filed Data -		DLN: 934913100:	L2538
TY 2017 Other Decreases Scho	edule			
Name	The law Cour	dakan Taa		
Name:	The Jain Foun	gation tuc		
EIN:	20-0284800			
Software ID:	17005038			
Software Version:	2017v2.2			
De	escription		Amount	
Cost basis adjustment				200

efile GRAPHIC print - DO NOT PROCESS	As Filed Data -		DLN:	93491310012538	
TY 2017 Other Expenses Sche	dule			_	
Name:	: The Jain Foundation Inc				
EIN:	20-0284800				
Software ID:	17005038				
Software Version:	2017v2.2				
Other Expenses Schedule					
Description	Revenue and Expenses per Books	Net Investment Income	Adjusted Net Income	Disbursements for Charitable Purposes	

Other Expenses Schedule							
Description	Revenue and Expenses per Books	Net Investment Income	Adjusted Net Income	Disb			
Clinical Outcome Study direct costs	30,336						

Other Expenses Schedule				
Description	Revenue and Expenses per Books	Net Investment Income	Adjusted Net Income	Di
Clinical Outcome Study direct costs	30,336			

Insurance

Office Expenses

Patient Diagnosis & Recruitment

·	Expenses per Books	Income	Income	Charitable Purposes
Clinical Outcome Study direct costs	30,336			30,336
Computer Services	4,777			4,777
CRO Charles River Research Discovery Ser	522,504			522,504

Computer Services	4,777		4,777
CRO Charles River Research Discovery Ser	522,504		522,504
CRO Evotec AG	22,232		22,232
CRO Jackson Laboratories	295,130		295,130

CRO Evotec AG	22,232		22,232
CRO Jackson Laboratories	295,130		295,130
CRO MRM Proteomics	142,543		142,543

CRO Jackson Laboratories	295,130		295,130
CRO MRM Proteomics	142,543		142,543
CRO Proof Center of Excellence	23,000		23,000

6,815

5,743

17,973

6,815

5,743

17,973

Description **Net Investment Adjusted Net** Disbursements for Revenue and Charitable Expenses per Income Income Books Purposes

16,051

1,097 83,998

5,568

31,814

16,051 1.097 83,998

Telephone & Internet 5.568

Website design & Software 31,814

Other Expenses Schedule

Postage, shipping, delivery

Printing & Publications

Research Tools

TY 2017 Other Income Schedule						
Name:	The Jaın Fo	undation Inc				
EIN:	20-0284800	)				
Software ID:	17005038					
Software Version:	2017v2.2					
Other Income Schedule						
Description		Revenue And	Net Investment	Adjusted Net Income		

**Expenses Per Books** 

36,139

Income

DLN: 93491310012538

Unused Grant Funds Return

efile GRAPHIC print - DO NOT PROCESS	As Filed Data -		DI	LN: 934913100125	38ز			
TY 2017 Other Liabilities Schedule								
Name:	The Jain Found	dation Inc						
EIN:	20-0284800							
Software ID:	17005038							
Software Version:	2017v2.2							
Description		Beginning of Year - Book Value	End of Year - Book Value					
Rounding					1			

efile GRAPHIC print - DO NOT PROCE	SS As Filed Data	-1	DLN	N: 93491310012538					
TY 2017 Other Professional Fees Schedule									
Name: The Jain Foundation Inc									
<b>EIN:</b> 20-0284800									
<b>Software ID:</b> 17005038									
Software Version: 2017v2.2									
Category	Amount	Net Investment Income	Adjusted Net Income	Disbursements for Charitable					
				Purposes					
Josh Thayer, Consultant	35,004	0	0	35,004					
Nupur Garg, PhD	14,085	0	0	14,085					
Other Consultants/Interns	6,045	0	0	6,045					

efile GRAPHIC print - DO NOT PROCESS	S As Filed Data	-	DLI	DLN: 93491310012538	
TY 2017 Taxes Schedule					
Nam	Name: The Jain Foundation Inc				
EI	<b>1:</b> 20-0284800				
Software I	<b>D:</b> 17005038				
Software Versio	<b>n:</b> 2017v2.2				
Category	Amount	Net Investment Income	Adjusted Net Income	Disbursements for Charitable Purposes	
Estimated Excise tax 2017	80,000				
Other tax	224				